Amendment to BULLETIN # 130

Manitoba Drug Benefits Formulary and Interchangeability Formulary Amendments

The following amendments will take effect on February 22, 2024



The amended Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary will be available on the Manitoba Health website <u>http://www.gov.mb.ca/health/mdbif</u> on the effective date of February 22, 2024

Bulletin #130 is currently available for download: http://www.gov.mb.ca/health/mdbif/bulletin130.pdf

Part 2 Additions

02522896	Jamp Tofacitinib	tofacitinib	5 mg	Tablet	JPC					
(a) For the treatment of patients 18 years of age or older who have moderate to severe active										

rheumatoid arthritis and have:

(i) failed treatment with at least 3 DMARD therapies, one of which is methotrexate and/or leflunomide, unless intolerance or contraindications to these agents is documented.

(ii) tried one combination therapy of DMARDS, and

(iii) documented disease activity (such as the number of tender joints, the number of swollen joints, the erythrocyte sedimentation rate or the C-reactive protein value).

NOTE: Coverage will be provided only if prescribed by a specialist in rheumatology.

Combined use with other biologic drugs or Janus Kinase (JAK) inhibitors will not be reimbursed.

(b) For the treatment of patients 18 years of age or older with moderate to severe active ulcerative colitis who have had inadequate response, intolerance or contraindications to conventional therapy including 5-aminosalicylate compounds AND corticosteroids.

NOTE: Coverage will be provided only if prescribed by a specialist in gastroenterology.

Interchangeable Product Price Changes

The following changes in price have occurred:						(\$ + 5%)
02488353	Mar-Trospium	trospium chloride	20 mg	Tablet	0.4072	**0.4276
02425947	Mint-Hydrochlorothiazide	valproic acid	12.5 mg	Tablet	0.0079	**0.0083

** The price has resulted in a change to the lowest price in the category.